Oscotec Inc. (039200.KQ)
KOSDAQ - KOSDAQ Delayed price. Currency in KRW
Add to watchlist
At close: 03:30PM KST
| Previous close | 41,200.00 |
| Open | 41,000.00 |
| Bid | 41,450.00 x N/A |
| Ask | 41,500.00 x N/A |
| Day's range | 40,650.00 - 42,050.00 |
| 52-week range | 18,000.00 - 44,900.00 |
| Volume | |
| Avg. volume | 563,261 |
| Market cap | 1.567T |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41,500.00 |
PR NewswireFDA Grants Orphan Drug Designation to Cevidoplenib for ITP
Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immune thrombocytopenia (ITP).
PR NewswireOscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease
Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer's disease (AD).
© 2024 Yahoo. All rights reserved.